Abstract: A silicate-based composition includes, in mol.%: 35-65% SiO2, 20-40% CaO, 10-30% Na2O, 0-15% TiO2, >0-15% Al2O3, 0-10% P2O5, 0-15% ZrO2, and 0-3% SnO2. A method of forming a silicate-based composition includes ceramming a silicate-based composition such that the ceramming is a cycle has a first portion and a second portion, with the first portion conducted at a first temperature for a first time and the second portion conducted at a second temperature for a second time.

Abstract: Provided are compounds represented by general formula (I), which can be used for treating ATR kinase-mediated diseases, such as proliferative diseases, such as cancer. Further provided are a pharmaceutical composition of the compound represented by general formula (I), a use thereof in treating ATR kinase-mediated diseases, and a preparation thereof.

Abstract: This application provides a display panel and a terminal device. The display panel is provided with an effective display region, a hole-punch region located in the effective display region, and a border region surrounding the hole-punch region. The effective display region is provided with a plurality of first traces extending in a first direction, and second traces extending in a second direction, where the first direction is perpendicular to the second direction. In at least a portion of the first traces whose extension directions pass through the hole-punch region, portions of each first trace respectively arranged on two sides of the hole-punch region are connected by one of first windings, to ensure that the portions of the first trace respectively arranged on the two sides of the hole-punch region are connected, and at least a portion of the first windings are located in the effective display region.

Abstract: According to one embodiment, a glass may include from about 50 mol. % to about 70 mol. % SiO2; from about 12 mol. % to about 35 mol. % B2O3; from about 4 mol. % to about 12 mol. % Al2O3; greater than 0 mol. % and less than or equal to 1 mol. % alkali metal oxide, wherein Li2O is greater than or equal to about 20% of the alkali metal oxide; from about 0.3 mol. % to about 0.7 mol. % of Na2O or Li2O; and greater than 0 mol. % and less than 12 mol. % of total divalent oxide, wherein the total divalent oxide includes at least one of CaO, MgO and SrO, and wherein a ratio of Li2O (mol. %) to (Li2O (mol. %)+(Na2O (mol. %)) is greater than or equal 0.4 and less than or equal to 0.6. The glass may have a relatively low high temperature resistivity and a relatively high low temperature resistivity.

Abstract: An article comprises a glass substrate. The glass substrate has a first surface having a plurality of vias therein, and a second surface parallel to the first surface. At least one of the first surface and the second surface is an etched surface having a surface roughness (Ra) of 0.75 nm or less. The glass substrate comprises, in mol percent on an oxide basis: 65 mol %?SiO2?75 mol %; 7 mol %?Al2O3?15 mol %; 26.25 mol %?RO+Al2O3?B2O3; 0 mol %?R2O?2 mol %. RO=MgO+CaO+SrO+BaO+ZnO. R2O=Li2O+Na2O+K2O+Rb2O+Cs2O.

Abstract: A borosilicate-based composition, including: 50-85 mol. % SiO2, 10-40 mol. % B2O3, >0-5 mol. % SnO2, and >0-20 mol. % of at least one alkali oxide selected from Li2O, Na2O, K2O, Rb2O, and Cs2O, such that the composition has a Young's Modulus less than 64 GPa.

Abstract: Methods for manufacturing glass articles having a target effective coefficient of thermal expansion CTETeff averaged over a temperature range comprise selecting a glass core composition having an average core glass coefficient of thermal expansion CTEcore that is greater than the target effective CTETeff and a glass clad composition having an average clad glass coefficient of thermal expansion CTEclad that is less than the target effective CTETeff; and manufacturing a glass laminate comprising a glass core layer formed from the glass core composition and two or more glass cladding layers fused to the glass core layer, each of the two or more glass cladding layers formed from the glass clad composition such that a ratio of a thickness of the glass core layer to a total thickness of the two or more glass cladding layers is selected to produce the glass laminate having an effective coefficient of thermal expansion CTEeff that is within ±0.5 ppm/° C. of the target effective CTETeff.

Abstract: A non-destructive testing method of analyzing a sample comprising a composite material is disclosed. The method comprises: emitting an electromagnetic signal onto the sample, the electromagnetic signal having a range of frequencies; detecting a response signal transmitted and/or reflected by the sample in response to the electromagnetic signal; processing the response signal to determine variation with frequency of a dielectric permittivity of the sample over the range of frequencies; and determining an indication of a structural characteristic of the sample from a measure of the variation with frequency of the dielectric permittivity of the sample.

Abstract: A stability measuring method for a synchronous generator includes: S11: collecting electrical quantities, and setting an alarm PQ curve of the synchronous generator; S12: calculating a dynamic reactive power reserve, an inductive dynamic reactive power reserve and a capacitive dynamic reactive power reserve of the synchronous generator; S13: calculating a dynamic reactive power reserve target value, an inductive dynamic reactive power reserve target value and a capacitive dynamic reactive power reserve target value of the synchronous generator; and S14: calculating a capacitive stability, an inductive stability and a stability of the synchronous generator.

Abstract: This invention relates to compounds of general Formula I in which A, R1, R2, R3 and R4 are as defined herein, and the pharmaceutically acceptable salts thereof; to pharmaceutical compositions comprising such compounds and salts; to methods of using such compounds, salts and compositions for treating pulmonary hypertension and related diseases, like pulmonary arterial hypertension; to methods of using such compounds, salts and compositions for treating abnormal cell growth, such as cancer; and to processes to make such compounds, salts and compositions.

Abstract: A compound compound having the structure: or a pharmaceutically acceptable salt thereof, wherein X is N or CR, where R is hydrogen, deuterium, C1-C4 alkyl, C1-C4 alkoxy, C3-C6 cycloalkyl, aryl, heteroaryl, aryl(C1-C6 alkyl), CN, amino, alkylamino, dialkylamino, CF3, or hydroxyl; A is selected from the group consisting of a bond, C?O, —SO2—, —(C?O)NR0—, and —(CRaRb)q—, where R0 is H or C1-C4 alkyl, and Ra and Rb are independently hydrogen, deuterium, C1-C6 alkyl, C3-C6 cycloalkyl, aryl, aryl(C1-C6 alkyl), heteroaryl, (C1-C6 alkyl)heteroaryl, etc.

Abstract: Methods of treatment as Janus Kinase inhibitors containing the compound of the invention having the structure: or a pharmaceutically acceptable salt thereof, wherein X is N; A is selected from the group consisting of a bond and C?O; R1 is C3-C6 cycloalkyl, wherein said cycloalkyl is further optionally substituted with one or more halo; R2 is hydrogen; R3 is hydrogen; R4 is monocyclic heteroaryl wherein said heteroaryl is optionally substituted with one or more C1-C6 alkyl; and, R5 is hydrogen; and, j is 0 or 1.

Abstract: The present invention provides methods or kits with inflammatory cytokines to pretreat 1-ISCs to augment their immune modulatory effect, in prevention and treatment of various diseases such as multiple sclerosis, arthritis, lupus, sepsis, hepatitis, cirrhosis, Parkinson's disease, chronic infections, and GvHD. The present invention relates to novel methods for enhancing the immunosuppressive or the immune stimulatory activities of mesenchymal stem cells (JvfSCs).

Abstract: The present invention provides methods or kits with inflammatory cytokines to pretreat 1-ISCs to augment their immune modulatory effect, in prevention and treatment of various diseases such as multiple sclerosis, arthritis, lupus, sepsis, hepatitis, cirrhosis, Parkinson's disease, chronic infections, and GvHD. The present invention relates to novel methods for enhancing the immunosuppressive or the immune stimulatory activities of mesenchymal stem cells (JvfSCs).

Abstract: A controller for vehicle air conditioner includes a base defining a mounting cavity; a knob assembly rotatably mounted to the base, wherein at least a portion of the knob assembly is located in the mounting cavity; and at least one bearing element arranged between the base and the knob assembly. Such a design reduces the friction between the base and the knob assembly and thus reduces the noise.

Abstract: Ion-exchanged alkali aluminosilicate glass articles with a ratio of peak compressive stress value to Young's modulus value of 14 or more. The glass articles may include Al2O3 mol %+RO mol %?18 mol %, where RO mol %=MgO mol %+CaO mol %, and be substantially free of ZnO, SrO, BaO, B2O3, P2O5, Li2O, and K2O. The glass articles may have a peak compressive stress value in a range of 850 MPa to 1400 MPa. The glass articles are suitable for various high-strength applications, including cover glass applications that experience significant bending stresses during use, for example, cover glasses for flexible displays.

Abstract: A compound having the structure: or an acceptable salt thereof, wherein X is N or CR, where R is hydrogen, alkyl, etc.; A is selected from the group consisting of a bond, C?O, —SO2—, etc.; A? is selected from the group consisting of a bond, C?O, etc.; Z is —(CH2)h— or a bond, etc.; R1 and R1? are independently selected from the group consisting of hydrogen, alkyl, etc.; R2 is selected from hydrogen, alkyl, etc.; R3 is selected from the group consisting of hydrogen, and amino; R4 is monocyclic or bicyclic, etc.; R5 is independently selected from hydrogen, alkyl, etc.; h, j, k, m, n and q are integers as defined in the specification. Also provided are methods of treatment as Janus Kinase inhibitors and pharmaceutical compositions containing the compounds of the invention and combinations with other therapeutic agents.

Abstract: Methods of forming a MTJ dummy fill gradient across near-active-MRAM-cell periphery and far-outside-MRAM logic regions and the resulting device are provided. Embodiments include providing an embedded MRAM layout with near-active-MRAM-cell periphery logic and far-outside-MRAM logic regions; forming a MTJ structure within the layout based on minimum space and distance rules relative to a first metal layer, a second metal layer, and/or both the first and second metal layers; forming a high-density MTJ dummy structure in the near-active-MRAM-cell periphery logic region based on second minimum space and distance rules relative to a first metal layer, a second metal layer, and/or both the first metal layer and the second metal layer; and forming a low-density MTJ dummy structure in the far-outside-MRAM logic region based on third minimum space and distance rules relative to a first metal layer, a second metal layer, and/or both the first metal layer and the second metal layer.

Abstract: A method for preparing a polyolefin resin powder has the steps of a) heat dissolving a polyolefin resin in an organic solvent having a solubility parameter less than or equal to the solubility parameter of the polyolefin resin to obtain a polyolefin resin solution; b) cooling the polyolefin resin solution to precipitate a solid, thereby obtaining a solid-liquid mixture; c) optionally adding an adjuvant to the solid-liquid mixture and mixing; and d) conducting solid-liquid separation and drying to obtain a polyolefin resin powder suitable for selective laser sintering. The difference between the solubility parameters of the organic solvent and of the polyolefin resin is within 0-20% of the solubility parameter of the polyolefin resin. The polyolefin resin powder obtained according to this method has good antioxidant property, good powder flowability, moderate size, smooth surface, suitable bulk density, and suitable dispersibility and particle size distribution.

Abstract: The present invention provides methods or kits with inflammatory cytokines to pretreat 1-ISCs to augment their immune modulatory effect, in prevention and treatment of various diseases such as multiple sclerosis, arthritis, lupus, sepsis, hepatitis, cirrhosis, Parkinson's disease, chronic infections, and GvHD. The present invention relates to novel methods for enhancing the immunosuppressive or the immune stimulatory activities of mesenchymal stem cells (JvfSCs).